In 688,183 Medicare patients given intravenous iron, the risk of anaphylaxis at first exposure was 68 per 100,000 for iron dextran against 24 per 100,000 for the non-dextran products combined.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Iron dextran' with aliases INFeD, Dexferrum, Cosmofer, iron(III)-dextran complex, high/low molecular weight iron dextran · 2026-09-27 12:04 · somebody
kind set kind set to mineral: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: In 688,183 Medicare patients given intravenous iron, the risk of anaphylaxis at first exposure was 68 per 100,000 for ir · 2026-09-27 12:04 · somebody
fact added summary: Serious adverse events with iron dextran have been attributed to its high-molecular-weight preparations; a review argued · 2026-09-27 12:04 · somebody
citation added pmid 26575062 cited as established: Iron dextran carries the highest anaphylaxis risk among intravenous iron products (Medicare cohort) · 2026-09-27 12:04 · somebody
citation added pmid 18274543 cited as emerging: Low-molecular-weight iron dextran and iron sucrose have similar safety profiles in CKD (review) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.